Humira Buyers Say They've Proven AbbVie's 'Patent Thicket'

By Nadia Dreid · November 25, 2019, 9:31 PM EST

AbbVie shouldn't be able to escape first-of-its-kind litigation accusing the pharmaceutical giant of building a "patent thicket" around its immunosuppressant Humira in order to block cheaper biosimilars from coming onto the...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Memorandum

Case Information

Case Title

In Re: Humira (Adalimumab) Antitrust Litigation

Case Number

Court

Illinois Northern

Nature of Suit

410(Anti-Trust)

Date Filed

March 18, 2019

Recent Articles By Nadia

November 19, 2024
DC Circ. Wonders Where To Land On Terrorism Liability Claims
November 07, 2024
Sutter Health Could Face Retrial On Antitrust Claims In March
July 17, 2024
Teladoc Hit With Another Investor Suit Over BetterHelp Woes
July 11, 2024
Pfizer's $50M EpiPen Deal Gets Final OK In Antitrust Suit
June 27, 2024
Judge OKs $10M Deal In Generic Price-Fixing MDL
April 16, 2024
NC Treasurer Backs FTC On Hospital Merger Challenge
April 09, 2024
White House, Senate Dems Want $1.3B To Fight COVID Fraud
March 01, 2024
NY Judge Tosses $6.4B BMS Investor Action For Good
February 21, 2024
39 AGs Call For Federal Pharmacy Benefit Manager Reform
February 05, 2024
States Ask Justices To End Feds' Alleged Online Censorship